Researcher Profile

Researcher Profile

Salah Almokadem, DO, MBChB

Salah Almokadem, DO, MBChB

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Head and Neck Cancer
Thoracic Cancer
sma11@psu.edu

Research Interests

  • Therapeutics
  • Neoplasms
  • Squamous Cell Carcinoma
  • Non-Small Cell Lung Carcinoma
  • Lung Neoplasms
  • Pharmacokinetics
  • Integrins
  • Safety
  • Clinical Trials
  • Survival
  • Cell Cycle Proteins
  • Immunotherapy

Clinical Trials

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Recent Publications

2019

KEYNOTE-040 investigators 2019, 'Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study', The Lancet, vol. 393, no. 10167, pp. 156-167. https://doi.org/10.1016/S0140-6736(18)31999-8

2017

Liu, J, Goldenberg, D, Almokadem, S, Crist, H & Mackley, H 2017, 'Long-term recurrence-free survival after an unplanned reduction in radiotherapy for HPV-positive oropharyngeal SCC: Two cases and a review of the literature' Ear, Nose and Throat Journal, vol. 96, no. 7, E23.
Stoller, R, Schmitz, JC, Ding, F, Puhalla, S, Belani, C, Appleman, L, Lin, Y, Jiang, Y, Almokadem, S, Petro, D, Holleran, J, Kiesel, BF, Ken Czambel, R, Carneiro, BA, Kontopodis, E, Hershberger, PA, Rachid, M, Chen, A, Chu, E & Beumer, JH 2017, 'Phase I study of veliparib in combination with gemcitabine', Cancer Chemotherapy and Pharmacology, vol. 80, no. 3, pp. 631-643. https://doi.org/10.1007/s00280-017-3409-3

2016

Liu, X, Rice, SJ, Jamis-Dow, CA, Abendroth, C, Ali, S, Almokadem, S & Belani, C 2016, 'A patient with complex multiple genomic alk alterations' Thorax, vol. 71, no. 4, pp. 383-385. https://doi.org/10.1136/thoraxjnl-2015-207950
Aronson, KR, Wagstaff, DA, Farace, E, Muscat, J, Belani, C, Almokadem, S & Fossum, T 2016, 'A week in the life of lung cancer survivors: Daily reports of stress, worry, mood, and symptoms', Journal of Health Psychology, vol. 21, no. 10, pp. 2269-2282. https://doi.org/10.1177/1359105315574921
Almokadem, S 2016, 'Progress in immunotherapy of head and neck squamous cell carcinoma', Current Molecular Pharmacology, vol. 9, no. 3, pp. 226-230. https://doi.org/10.2174/1874467208666150716120658

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)